Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Pancreatic Neoplasms 7Breast Neoplasms 6Ovarian Neoplasms 5Stomach Neoplasms 4Colonic Neoplasms 4Rectal Neoplasms 3Lung Neoplasms 3Neoplasm Metastasis 2Melanoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Zollinger-Ellison Syndrome 1Vipoma 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Somatostatinoma 1Renal Insufficiency 1Prostatic Neoplasms 1Pheochromocytoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Locally Advanced Rectal Cancer 1Liver Neoplasms 1Liver Failure 1

Interventions

Temozolomide 2Capecitabine 2veliparib 1Omeprazole 1Lansoprazole 1Esomeprazole 1Dexlansoprazole 1Clopidogrel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Zollinger-Ellison Syndrome × veliparib × Gastrointestinal × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡